Delivery of A4GALT targeting siRNA-lipid nanoparticle rescues fabry disease phenotypes in hiPSC derived endothelial cell and podocyte models
In this study, we explore the therapeutic feasibility of globotriaosylceramide (Gb3) synthase (A4GALT)-specific siRNA-loaded polyhistidine (pHis)-incorporated lipid nanoparticles (HLNPs) for Fabry disease (FD). HLNPs were developed to deliver siRNAs targeting A4GALT using a microfluidic device, with pHis aiding in endosome escape. The therapy was tested on GLA-knockout human induced pluripotent stem cell-derived endothelial cells (GLA-KO-hiPSC-ECs) and podocytes (GLA-KO-hiPSC-PCs). GLA-KO-hiPSCs-ECs or -PCs, upon differentiation, were treated with A4GALT-siRNA-HLNP. Successful intracellular uptake of A4GALT-siRNA-HLNP was confirmed through fluorescence and electron microscopy in both cell types. A4GALT-siRNA-HLNP treatment confirmed both cell types' stability at 5 µg/mL. Increased Gb3 deposition and zebra body formation were detected in both cell types, but A4GALT-siRNA-HLNP treatment attenuated these FD phenotypes, demonstrating reduced expression of A4GALT through western blot analysis. RNA sequencing analysis revealed that the expression of transcripts associated with FD in both cell types was restored by A4GALT-siRNA-HLNP treatment. Suppression of A4GALT via siRNA/HLNP treatment significantly rescued FD phenotypes, presenting a novel therapeutic approach for FD. Overall design: To investigate the transcriptomic alterations ensuing from A4GALT suppression via siRNA-HLNP in the context of GLA loss-of-function, RNA sequencing analysis was conducted on hiPSC-EC and hiPSC-PC.